Whitehawk Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-20.6M | $-63.7M | $-65.8M | $-60.5M | $-110.1M | $-3.5M | $-23.3M | $-10.4M |
| Depreciation & Amortization | $79.0K | $193.0K | $169.0K | $159.0K | $105.0K | $9.0K | — | — |
| Depreciation | $100.0K | $200.0K | $200.0K | $100.0K | — | $61.5K | $76.5K | $46.7K |
| Amortization | — | — | $0 | $87.0K | $95.0K | $0 | — | — |
| Stock-Based Compensation | $9.9M | $10.8M | $12.0M | $9.6M | $2.1M | $139.0K | $1.1M | $3.4M |
| Net Cash from Operating Activities | $-97.4M | $-59.6M | $-59.7M | $-49.6M | $-22.4M | $-12.7M | $-23.9M | $-5.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $552.0K | $1.7M | $4.0M | $444.0K | $46.0K | $19.0K | $237.0K | $37.9K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $11.9M | $25.2M | $83.2M | $-132.9M | $25.2M | $-19.0K | $-237.0K | $-37.9K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | $0 | $4.4M | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $94.4M | $130.0K | $326.0K | $72.6M | $141.8M | $1.2M | — | $48.2M |
| Net Change in Cash | $8.8M | $-34.2M | $23.9M | $-109.9M | $144.5M | $-11.5M | $-24.1M | $42.3M |
| Free Cash Flow | $-98.0M | $-61.2M | $-63.6M | $-50.1M | $-22.5M | $-12.7M | $-24.1M | $-5.8M |